CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 56 enrolled
Drug / intervention
0.25% Bupivacaine + Clonidinedrug
Likely dose
0.25% Bupivacaine + Clonidine 2mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01638052
NCT01638052Phase 2Completed

Great Auricular Nerve Block for Children Undergoing Tympanomastoid Surgery: Does the Addition of Clonidine Increase the Duration of Postoperative Analgesia?

Ann & Robert H Lurie Children's Hospital of Chicago·interventional·Posted Jul 11, 2012·Updated Aug 4, 2021

In Brief

A Phase 2 clinical trial evaluating 0.25% Bupivacaine + Clonidine for Tympanomastoid Surgery and 3 related conditions. Completed, enrolled 56 participants across 1 site.

Detailed Summary

The investigators goal is to determine the efficacy and duration of analgesia with the addition of Clonidine, an alpha-2 agonist, to local anesthetic blockade using bupivacaine, of the great auricular nerve in children undergoing tympanomastoid surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 11, 2012
Enrollment StartFeb 1, 2006
Primary CompletionMar 1, 2008
Study CompletionApr 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 14.0 years ago

Interventions

0.25% Bupivacaine + Clonidinedrug

Patients will receive 2mL of 0.25% bupivacaine with 2mcg/ml of clonidine